Can we crystallize the role of urate-lowering treatment in chronic kidney disease?
- 19 February 2025
- journal article
- Published by Elsevier in Kidney International
- Vol. 107 (3) , 394-396
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Enterprise Ireland
- Astellas Pharma
- Health Research Board
This publication has 10 references indexed in Scilit:
- Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapyKidney International, 2024
- Combination Treatment with Verinurad and Allopurinol in CKDJournal of the American Society of Nephrology, 2024
- Hyperuricaemia and gout in cardiovascular, metabolic and kidney diseaseEuropean Journal of Internal Medicine, 2020
- Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2020
- Effects of Allopurinol on the Progression of Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort studyBMJ Open, 2019
- The case for uric acid-lowering treatment in patients with hyperuricaemia and CKDNature Reviews Nephrology, 2019
- Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized TrialAmerican Journal of Kidney Diseases, 2018
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutNew England Journal of Medicine, 2018
- Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysisPLOS ONE, 2017